The activity is largely driven by routine tax settlements following equity vesting, which is common and not necessarily indicative of negative sentiment. However, the size of the open-market sales by two executives warrants monitoring for potential follow-up transactions or commentary around corporate performance.
ANIP drugs
ANIP drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 4 $76.53entry
- T+1 · 9mo ago −1.22%α −0.66% · $75.60
- T+5 · 9mo ago −0.31%α +0.97% · $76.29
- T+20 · 8mo ago −0.74%α +3.62% · $75.96
- T+60 · 6mo ago +2.59%α −7.83% · $78.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple executives at ANI Pharmaceuticals, including the CEO, CFO, and other senior leaders, engaged in tax-related share withholdings and open-market sales over the past week. The total value of transactions exceeds $2.6 million, with $913,092 in open-market sales and $1.7 million in tax withholding dispositions.
Key Financial Metrics
Key Facts
- CEO Nikhil Lalwani surrendered 17,060 shares ($1.26M) for tax withholding.
- CFO Stephen Carey and other SVPs also surrendered shares for tax purposes, totaling $1.7M across four executives.
- Two executives, Christopher Mutz and Krista Davis, conducted open-market sales totaling $913,092.
- All open-market sales occurred at prices between $74.13 and $75.00.
- No purchases or positive transactions were reported.
Financial Impact
$2.6M total insider activity over 7 days, including $913K in open-market sales and $1.7M in tax-related share dispositions
Risk Factors
- Perception of insider selling could weigh on investor sentiment, especially given the high dollar volume.
- Absence of any insider buying may signal lack of near-term confidence, though not conclusive.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-ANIP-1773173388948 |
Track record
34 reports on ANIP
4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 12 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers